Abstract
This work describes a novel, druggable UHRF1/DNMT1/GLI complex that regulates SHH-dependent tumor growth, and highlights an FDA-approved drug capable of disrupting this complex to attenuate tumor growth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have